ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics director Jerrold B. Grossman bought additional shares of company stock. On May 12, 2026, he made an open-market purchase of 12,500 shares of ADMA common stock at $8.01 per share. Following this transaction, he directly holds 513,884 common shares, which includes 10,690 RSUs granted on February 9, 2026 that vest in two equal installments on August 9, 2026 and February 9, 2027, along with 503,194 owned shares. He also has several indirect holdings: 175 shares through Brookwood LLC, 38,294 shares through the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares owned by his wife.
ADMA Biologics director Jerrold B. Grossman bought 12,500 shares of common stock in an open-market transaction at $8.01 per share. Following this purchase, his directly owned stake shown in the filing increased to 501,384 shares of ADMA common stock.
The filing also lists additional ADMA shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, reflecting interests associated with the director beyond his direct holdings.
ADMA Biologics reported strong profitability on flat revenue for the quarter ended March 31, 2026. Total revenue was $114.5 million, essentially unchanged year over year, but product mix shifted sharply. ASCENIV sales rose to $97.5 million, up 27.7%, while other IVIG and intermediates declined.
Gross profit increased to $80.8 million and gross margin expanded significantly, helped by ASCENIV growth and the new yield‑enhanced manufacturing process. Net income rose to $45.3 million, compared with $26.9 million a year earlier, with diluted EPS of $0.19.
ADMA used leverage to fund capital returns. It drew $125.0 million on its JPM revolving facility and repurchased 6.8 million shares for $111.1 million, including an accelerated share repurchase. Cash ended at $138.2 million, while total debt increased to $196.9 million.
The company also sold three plasma centers for $12.0 million, recognizing about $8.0 million gain, and later obtained FDA approval to expand ASCENIV’s label to children two years and older.
ADMA Biologics reported first quarter 2026 results showing flat revenue but sharply higher profitability. Total revenue was $114.5 million, essentially unchanged from $114.8 million a year earlier, as 28% growth in ASCENIV sales to $97.5 million offset a 54% decline in revenue from another immunoglobulin product and lower intermediates revenue.
Gross profit rose to $80.8 million and gross margin expanded to 71% from 53%, helped by a richer ASCENIV mix and prior manufacturing improvements. GAAP net income increased to $45.3 million from $26.9 million, while Adjusted Net Income reached $40.7 million and Adjusted EBITDA was $59.7 million, both growing more than 20% year over year. The company generated $58 million of operating cash flow and ended March 31, 2026 with $138.2 million of cash and cash equivalents.
Management reiterated confidence in ASCENIV demand and updated its full-year 2026 outlook to reflect competitive pressure in the U.S. immunoglobulin and plasma therapies market, while withdrawing longer-term guidance.
ADMA Biologics reports a key regulatory milestone for its ASCENIV immune globulin therapy. The U.S. Food and Drug Administration has approved a supplemental Biologics License Application expanding ASCENIV’s primary humoral immunodeficiency indication to pediatric and adult patients two years of age and older, from a prior minimum age of 12 years. The approval also fulfills the required pediatric post‑marketing commitment and allows updated prescribing information. ASCENIV is a patented, plasma-derived intravenous immune globulin designed to provide antibodies against infections, supported by an established safety profile that includes boxed warnings and detailed precautions typical for IVIG products.
ADMA Biologics Inc ownership update: Vanguard Capital Management reports beneficial ownership of 12,110,153 shares of Common Stock, representing 5.08% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 12,110,153 shares and sole voting power for 1,803,282 shares. The filing is signed by a Vanguard representative on 04/29/2026.
ADMA Biologics, Inc. is calling a virtual 2026 annual stockholder meeting on June 2, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/ADMA2026. Stockholders of record at the close of business on April 8, 2026, when 232,324,283 common shares were outstanding, may vote.
Investors will vote on electing two Class I directors, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The board, which currently has seven members in three staggered classes, recommends voting FOR all proposals.
The proxy describes ADMA’s governance structure, including fully independent Audit, Compensation, and Governance and Nominations Committees, and highlights a pay-for-performance philosophy that combines base salary, annual incentives, and multi-year equity awards. It also discloses major stockholders and equity plan capacity.
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina had 20,362 shares of common stock withheld at $9.11 per share to cover taxes on vesting restricted stock units. These shares were retained by the company to satisfy mandatory tax withholding and were not sold in the open market.
After this tax-withholding disposition, she directly holds 446,238 shares of ADMA common stock. Footnotes indicate this total includes multiple blocks of unvested restricted stock units that vest in quarterly installments over four years and common shares from prior option exercises and net share settlements.
ADMA Biologics filed a current report to furnish a press release responding to a short seller report by Culper Research. The company states it refutes key allegations about its business practices, operations and immune globulin portfolio, especially regarding its ASCENIV therapy for immune-compromised patients.
ADMA highlights that demand and utilization for ASCENIV have grown steadily over the past two years and are at a record high, and that distributor stocking levels align with industry standards and ASCENIV’s long production cycle. The release also reiterates ASCENIV’s FDA-approved indication, manufacturing approach, patent protection and important safety warnings, and provides an overview of ADMA’s broader plasma-derived biologics portfolio and development pipeline.